{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003849","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.872835+00:00","generated_at":"2026-06-01T08:02:48.745225+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio Pharma gets SMC OK to escalate PH-762 dose in Phase 1b; no dose-limiting toxicities","bullets":["Safety Monitoring Committee recommended dose escalation to next concentration after initial cohort.","No dose-limiting toxicities or clinically relevant treatment-emergent adverse events observed.","PH-762 intratumoral injections were well tolerated in the first dose cohort.","Phase 1b trial (NCT06014086) targets cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003849","json":"https://secwatch.observer/filing/0001683168-24-003849.json","markdown":"https://secwatch.observer/filing/0001683168-24-003849.md","text":"https://secwatch.observer/filing/0001683168-24-003849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824003849/0001683168-24-003849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316824003849/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:02:48.745225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}